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cord blood (UCB) transplantation (UCBT) have been conducted
and therefore how to choose between these alternative stem cell
sources is not known. Encouraging results of 60% long term
disease-free survival (DFS) or better have been achieved using
unrelated volunteer donors in highly selected patient groups such
as young patients with chronic myelogenous leukemia (CML) who
are transplanted early in their disease course using a 6/6 HLA-
matched donor. However, HLA-mismatch, poor disease risk, older
adult age and non-CML diagnosis are associated with a signiﬁ-
cantly worse outcome after unrelated BMT. Further, recently the
importance of matching for HLA class I as well as class II alleles
has been recognized. However, while matching at 8/8 HLA-A, B,
C and DRB1 (or 10/10 if DQ is included) is associated with
improved outcome, this strategy also reduces the “suitable” donor
pool and can potentially prolong the donor search. The 2002 GAO
report to Congress noted that despite considerable efforts on the
part of the National Marrow Donor Program (NMDP) the num-
ber of transplants facilitated by the NMDP “represent about one
tenth of those we estimate to be in need of unrelated donor
transplants”. As an alternative, UCB offers the potential to extend
the donor pool. However, UCB is limited by cell dose and HLA
match. For example, in a collaborative study led by the New York
Blood Center (NYBC), pediatric recipients of 6/6 UCB units had
a comparable and possibly improved outcome compared to
matched BM, and a comparable outcome if they received 5/6 UCB
units of at least 2.5  107 nucleated cells/kilogram (NC/kg).
Inferior outcome was associated with 5/6 units 2.5  107 NC/kg
or 4/6 units. Notably, in the 4/6 setting, high cell dose could at
least partially compensate for mismatch. Further NYBC analysis of
the outcome of US patients transplanted with myeloablative con-
ditioning and single units has demonstrated that a cell dose2.5
107 NC/kg is required in recipients of 5/6 units (bidirectional
mismatch) to achieve at least 50% survival at one year whereas in
4/6 recipients the cell dose needs to be at least 5  107 NC/kg to
achieve similar outcome. Therefore, not surprisingly, studies of
adult single unit UCBT which have involved 4-5/6 matched units
with a median cell dose of less than 2.5 have demonstrated poor
survival. However, the fact that adult UCBT has had a comparable
outcome to mismatched BM introduces UCB as a valid alternative
to mismatched BMT and calls for new strategies to improve adult
UCBT outcome. One possible strategy is double unit grafts which
have been associated with a 2-year DFS of 60% in 31 patients at
the University of Minnesota. This improved outcome is even
despite the low cell dose of the engrafting unit suggesting intrigu-
ing biology of this approach. Overall the minimum acceptable
criteria for both volunteer donor and UCB grafts have not been
deﬁned. Currently it is reasonable that all patients undergo a
volunteer and UCB search at referral. Donor choice will depend on
the patient diagnosis, the urgency of the transplant, the relative
availability of an adequately matched volunteer versus a UCB unit
of adequate dose and match, physician preference and research
priorities. A volunteer donor may be preferred for a patient with
CML in chronic phase or early accelerated phase and possibly for
other diagnoses such as myeloﬁbrosis or severe aplastic anemia. If
the transplant is urgent (required in less than 6 weeks) UCB has a
clear advantage although a volunteer donor could possibly be
obtained using the NMDP ultra fast search strategy. Acceptable
donors include readily available volunteers that are 7-8/8 matched
(or 9-10/10) and 5-6/6 UCBs 2.5  107 NC/kg or 4/6 5  107
NC/kg. Notably, given the interaction of HLA match and cell
dose, a better UCB unit may be smaller but better matched. If
selected volunteers become unavailable during the search then it is
appropriate to default to UCB to prevent an excessively long
search. In UCB selection issues other than HLA match and dose
are also important. It is ideal to perform conﬁrmatory typing from
an attached segment and given CD34 measurements are not
standardized they should not be used unless two units of similar
match and NC dose are available. Markers for infectious diseases
need to be complete and negative with bacterial and fungal culture
negative at freeze. In the future, greater information concerning
the factors determining outcome after volunteer donor and UCB
transplantation may guide more detailed algorithms for donor
selection.
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The ﬁeld of cord blood (CB) transplantation has come quite a
way since its inception and the ﬁrst clinical transplant in October
1988. CB hematopoietic stem (HSC) and progenitor (HPC) cells
have been used to treat a wide variety of genetic disorders and
malignancies. These transplants were possible because the cells
could be cryopreserved for prolonged periods of time and stored in
CB banks for future use. The vast majority of CB transplants have
been performed in children and low weight recipients. Fewer CB
transplants have been done in adults and higher weight individuals
because of the limiting numbers of CB cells that are available for
collection and storage at the birth of babies. A number of proce-
dures have been and are being investigated to enhance the efﬁ-
ciency of CB transplantation for adults. This includes attempts at
ex-vivo expansion of HSC, which has not yet provided a clinical
breakthrough because we don’t know enough of the biology re-
garding stem cell self-renewal and proliferation to truly expand the
HSC. Transplantation of multiple CB units is ongoing with early
clinical success, but this procedure has apparently not greatly
reduced the time to engraftment and only one of the transplanted
CB units seems to survive for longer term engraftment. Not all
mouse HSC home with absolute efﬁciency, effects consistent with
clinical experience in which limiting numbers of cells result in graft
failure. The chemokine stromal cell derived factor-1 (SDF-1)/
CXCL12 and its G protein–linked seven transmembrane span-
ning receptor CXCR4 are involved in chemotaxis, mobilization
and homing of HSC and HSC. CD26 is a cell surface dipepti-
dylpeptidase IV, which can truncate SDF-1/CXCL12. We found
that inhibition or deletion of CD26 on target populations contain-
ing or highly enriched for human CB and human and murine bone
marrow HSC/HPC greatly enhanced the chemotactic responsive-
ness of these cells to SDF-1/CXCL12. Inhibition/deletion of
CD26 in mice was associated with greatly decreased ability to
mobilize HPC with G-CSF. Based on these ﬁnds we hypothesized
that enhancement in homing of HSC to the bone marrow niche
needed for support of the self-renewal and proliferative capacity of
HSC would lead to increased engraftment with limiting numbers
of HSC. We tested this hypothesis, ﬁrst with mouse bone marrow
cells transplanted into lethally irradiated congenic mice in the
setting of non-competitive and also competitive repopulation, each
followed by repopulation in a non-competitive repopulation assay
in lethally irradiated secondary congenic mice. Mouse bone mar-
row donor cells pretreated with CD26 inhibitors Diprotin A (Ile-
Pro-Ile) or Val-Pyr or from CD26 gene knock-out (
/
) mice had
greatly enhanced capacity to home to the bone marrow of recipi-
ents, and this was associated with enhanced engraftment, especially
with dose-limiting numbers of donor cells. Recent work from our
laboratory has found that in vitro inhibition of CD26 on human
CD34 CB cells enhances engraftment of these cells in sublethally
irradiated NOD/SCID mice. These encouraging results with CB
cells suggest that targeting CD26, or other means to enhance
homing/engraftment may be of practical value in a clinical setting
to use limiting numbers of CB HSC for successful transplantation.
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The National Marrow Donor Program established a cord blood
banking program in 1999. Currently, 14 U.S. banks have joined the
network. A steering committee comprised of bank directors, lab-
oratory supervisors, ethicists, obstetricians, scientists, transplanters
and experts in information technology and regulatory affairs and ad
hoc representation from HRSA and the Navy was established and
meets on a quarterly basis. The purpose of the committee is to
advance cord blood transplantation, improve clinical practice and
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